EP3731837A4 - Combinaison contenant de la linagliptine et de la metformine - Google Patents

Combinaison contenant de la linagliptine et de la metformine Download PDF

Info

Publication number
EP3731837A4
EP3731837A4 EP18913688.0A EP18913688A EP3731837A4 EP 3731837 A4 EP3731837 A4 EP 3731837A4 EP 18913688 A EP18913688 A EP 18913688A EP 3731837 A4 EP3731837 A4 EP 3731837A4
Authority
EP
European Patent Office
Prior art keywords
linagliptin
metformin
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18913688.0A
Other languages
German (de)
English (en)
Other versions
EP3731837A2 (fr
Inventor
Ali TÜRKYILMAZ
Nur PEHLIVAN AKALIN
Merve ERGUN DONMEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3731837A2 publication Critical patent/EP3731837A2/fr
Publication of EP3731837A4 publication Critical patent/EP3731837A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP18913688.0A 2017-12-25 2018-12-21 Combinaison contenant de la linagliptine et de la metformine Pending EP3731837A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/21505A TR201721505A2 (tr) 2017-12-25 2017-12-25 Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon
PCT/TR2018/050857 WO2019194773A2 (fr) 2017-12-25 2018-12-21 Combinaison contenant de la linagliptine et de la metformine

Publications (2)

Publication Number Publication Date
EP3731837A2 EP3731837A2 (fr) 2020-11-04
EP3731837A4 true EP3731837A4 (fr) 2021-06-30

Family

ID=67900634

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18913688.0A Pending EP3731837A4 (fr) 2017-12-25 2018-12-21 Combinaison contenant de la linagliptine et de la metformine

Country Status (3)

Country Link
EP (1) EP3731837A4 (fr)
TR (1) TR201721505A2 (fr)
WO (1) WO2019194773A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022173406A1 (fr) * 2021-02-15 2022-08-18 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Procédé pour formulations de linagliptine ou d'un sel pharmaceutiquement acceptable de celle-ci
WO2023002036A1 (fr) * 2021-07-22 2023-01-26 Krka, D.D., Novo Mesto Procédé de préparation d'une composition pharmaceutique comprenant de la linagliptine et du chlorhydrate de metformine
WO2023075826A1 (fr) * 2021-10-28 2023-05-04 The Texas A&M University System Compositions de metformine stable et de produits médicamenteux similaires à contrôle d'impuretés nitroso
WO2023163510A1 (fr) * 2022-02-23 2023-08-31 주식회사 제뉴원사이언스 Formulation d'un complexe pharmaceutique à libération contrôlée de médicament comprenant de la linagliptine ou un sel de qualité pharmaceutique de celle-ci et de la metformine ou un sel de qualité pharmaceutique de celle-ci

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2848242A1 (fr) * 2013-09-12 2015-03-18 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations orodispersibles de Linagliptin
WO2015107536A2 (fr) * 2013-12-09 2015-07-23 Intas Pharmaceuticals Limited Combinaison de doses fixes contenant de la linagliptine et de la metformine hcl

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130137624A (ko) 2010-09-03 2013-12-17 브리스톨-마이어스 스큅 컴퍼니 수용성 항산화제를 사용한 약물 제제
WO2014080383A1 (fr) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Composition pharmaceutique d'inhibiteurs de la dipeptidyl-peptidase-iv (dpp-iv) en association avec d'autres antidiabétiques
WO2015110962A1 (fr) * 2014-01-21 2015-07-30 Wockhardt Limited Compositions pharmaceutiques orales solides comprenant une combinaison de doses fixes de metformine et de linagliptine ou de leurs sels

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2848242A1 (fr) * 2013-09-12 2015-03-18 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations orodispersibles de Linagliptin
WO2015107536A2 (fr) * 2013-12-09 2015-07-23 Intas Pharmaceuticals Limited Combinaison de doses fixes contenant de la linagliptine et de la metformine hcl

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019194773A2 *

Also Published As

Publication number Publication date
WO2019194773A2 (fr) 2019-10-10
WO2019194773A3 (fr) 2019-12-12
EP3731837A2 (fr) 2020-11-04
TR201721505A2 (tr) 2019-07-22

Similar Documents

Publication Publication Date Title
EP3508580A4 (fr) Nouveau promoteur et utilisation associée
IL278171A (en) Glucose-dependent insulin polypeptide and its uses
EP3665303A4 (fr) Agents de liaison à clec9a et utilisations associées
EP3889249A4 (fr) Exosome et utilisations diverses correspondantes
EP4076448A4 (fr) Oxadiazoles fluoroalkylés et leurs utilisations
EP3453401A4 (fr) Combinaison d'interleukine et utilisation de celle-ci
EP3611233A4 (fr) Encre et ensemble d'encres
EP3689936A4 (fr) Composition de polyisocyanate bloquée et son utilisation
EP3731837A4 (fr) Combinaison contenant de la linagliptine et de la metformine
EP3733849A4 (fr) Promoteur amélioré et utilisation associée
IL267184A (en) Phenylamidines and the use thereof as fungicides
EP3802613A4 (fr) Dimère et son utilisation
SG11201908281VA (en) Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
IL277502A (en) Compounds and uses for them
SG11202008543RA (en) Pyrrolidineamide derivatives and uses thereof
EP3901146A4 (fr) Composé phénylpyrrolidine et son utilisation
IL267258A (en) Phenoxyphenylamidines and the use thereof as fungicides
EP3766696A4 (fr) Stratifié, et application de celui-ci
EP3694519A4 (fr) Combinaison pharmaceutique comprenant de la dapoxétine et de la phosphodiestérase de type 5
EP3713465A4 (fr) Socle multifonction
IL280369A (en) Myokines and their uses
EP3744358A4 (fr) Élément de jonction de tissu et son utilisation
EP3703805A4 (fr) Administration assistée magnétiquement dans et à travers la peau
EP3634475A4 (fr) Réduction de la toxicité d'endotoxine d'agrobacterium
EP3694707A4 (fr) Phosphonates et leurs utilisations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200718

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210601

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/155 20060101AFI20210526BHEP

Ipc: A61K 31/522 20060101ALI20210526BHEP

Ipc: A61K 9/20 20060101ALI20210526BHEP

Ipc: A61P 3/10 20060101ALI20210526BHEP

Ipc: A61K 9/48 20060101ALI20210526BHEP

Ipc: A61K 47/22 20060101ALI20210526BHEP

Ipc: A61K 47/32 20060101ALI20210526BHEP

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231222